MiMedx's dHACM for plantar fasciitis featured in peer publication.
MiMedx announced that the positive pain and foot function results from its Phase 2B clinical trial of micronized dHACM in the treatment of Plantar Fasciitis have been published in the peer-reviewed journal, Foot & Ankle International. The publication of this data follows the company's late-March announcement that it achieved the primary and secondary efficacy endpoints in this Phase 2B study. The Phase 2B trial studied a single injection of 40 mg of micronized dHACM injection as compared to a single injection of saline placebo control in the treatment of Plantar Fasciitis. Completion of the Phase 3 clinical study is expected in 2019. The primary efficacy endpoint was the mean change in VAS score for pain between baseline and the 3-month follow-up visit. The baseline VAS and FFI-R scores were similar between groups. At the 3-month follow-up, the mean VAS score was reduced by 76% for patients in the Treatment Group compared with a 45% reduction for the Control Group, and the mean FFI-R score was reduced by 60% for patients in the Treatment Group, while the Control Group had mean reduction of 40% versus baseline. Overall, at the three-month study follow-up visit, 82.2% patients in the treatment group, and 47.2% patients in the control group reported at least a 50% reduction in VAS score from baseline.
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 2, 2018|
|Previous Article:||SenesTech files request for removal of 'Restricted Use Only' for ContraPest.|
|Next Article:||Schneider National reports Q2 adj. EPS 40c, consensus 36c.|